Incyte/$INCY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Ticker

$INCY
Primary listing

Industry

Biotechnology

Employees

2,617

Incyte Metrics

BasicAdvanced
$14B
726.51
$0.10
0.90
-

What the Analysts think about Incyte

Analyst ratings (Buy, Hold, Sell) for Incyte stock.

Bulls say / Bears say

Incyte's acquisition of Escient Pharmaceuticals for $750 million enhances its pipeline with promising small-molecule drugs for immune and neuro-immune disorders, potentially driving future growth. (seekingalpha.com)
The FDA's approval of Monjuvi (tafasitamab-cxix) in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma expands Incyte's oncology portfolio, offering new revenue streams. (businesswire.com)
The appointment of Bill Meury as CEO, with his extensive experience in biopharma acquisitions, signals a strategic shift towards potential mergers and acquisitions, which could bolster Incyte's market position. (seekingalpha.com)
Incyte's stock declined by 29.6% year-to-date as of October 2023, primarily due to pipeline setbacks and increased competition for its lead drug, Jakafi. (nasdaq.com)
The FDA's approval of GSK's Ojjaara, a once-daily oral JAK1/JAK2 inhibitor for myelofibrosis, introduces significant competition to Incyte's Jakafi, potentially impacting its market share. (nasdaq.com)
Incyte's fourth-quarter earnings fell short of expectations, with full-year guidance indicating a significant deceleration in growth for key products like Jakafi and Opzelura, raising concerns about future profitability. (financialcontent.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

Incyte Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Incyte Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INCY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs